News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EffRx Receives U.S. Orphan Drug Designation For EX404 For Treatment Of Pediatric Polycystic Ovary Syndrome


6/10/2014 9:59:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ZURICH--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
EffRx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES